A Phase 1/2, Multicenter, Dose-Escalation and Expansion Study of Combination Therapy With Venetoclax, Daratumumab and Dexamethasone (With and Without Bortezomib) in Subjects With Relapsed or Refractory Multiple Myeloma
Phase of Trial: Phase II
Latest Information Update: 13 Jul 2018
At a glance
- Drugs Daratumumab (Primary) ; Venetoclax (Primary) ; Bortezomib; Bortezomib; Dexamethasone; Dexamethasone
- Indications Multiple myeloma
- Focus Adverse reactions; Therapeutic Use
- Sponsors AbbVie
- 03 Jul 2018 Planned End Date changed from 15 Apr 2023 to 2 Jul 2023.
- 05 Jun 2018 Trial design presented at the 54th Annual Meeting of the American Society of Clinical Oncology.
- 22 Mar 2018 Status changed from not yet recruiting to recruiting.